CBP

Bounce Imaging Releases New TSM®-Enabled 360° Cameras Powered by TrellisWare; Part of $11M in New Contracts with DoD

Retrieved on: 
星期二, 五月 7, 2024
Army, Radio, MANET, FBI, ATAK, UGV, Intelligence, TSM, CBP, USAF, UAS, NYPD, Satellite navigation device

An order for several hundred of these systems to U.S. special operations units represents the largest part of $11 million in new DoD contracts awarded to Bounce Imaging, with shipments beginning this month.

Key Points: 
  • An order for several hundred of these systems to U.S. special operations units represents the largest part of $11 million in new DoD contracts awarded to Bounce Imaging, with shipments beginning this month.
  • The incorporation of this communication pathway facilitates seamless collaboration with other unmanned aerial systems (UAS) and unmanned ground vehicle (UGV) platforms as a long-range payload.
  • Deployable by tossing, tethering, or mounting, warfighters can evaluate environmental circumstances from all angles simultaneously before engaging.
  • Bounce Imaging tactical cameras support domestic operations every day with over 600 federal, state, and local law enforcement agencies such as the FBI, CBP, NYPD and others across the United States.

Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update

Retrieved on: 
星期一, 五月 6, 2024
Chromatin, Protein, SMARCA4, BRG1, Security, Research, SMARCA2, IND, Prostate cancer, LDAC, Acetyltransferase, BRM, AACR, Lung cancer, Multiple myeloma, AML, CBP, ARID1B, Lilly, Complex, Merck, NSCLC, DLBCL, ARID1A, Survival, Thrombocytopenia, Therapy, Gene expression, Biology, Cancer, Prostate, Data, Patient, Selective, SWI/SNF, Neoplasm, MDS, Anemia, Pharmaceutical industry

In April 2024, Foghorn presented preclinical data highlighting pipeline progress from multiple potential first-in-class medicines, including the first presentation of preclinical data for FHD-909, at the 2024 American Association for Cancer Research (AACR) Annual Meeting held April 5-10, 2024.

Key Points: 
  • In April 2024, Foghorn presented preclinical data highlighting pipeline progress from multiple potential first-in-class medicines, including the first presentation of preclinical data for FHD-909, at the 2024 American Association for Cancer Research (AACR) Annual Meeting held April 5-10, 2024.
  • In April 2024, Foghorn hosted the first Future of Disease and Chromatin Regulation Summit at the Foghorn corporate headquarters in Cambridge, Massachusetts.
  • In April 2024, Foghorn appointed Kristian Humer as Chief Financial Officer.
  • In April, Foghorn presented new pharmacodynamic and pharmacokinetic preclinical data at the 2024 AACR Annual Meeting highlighting:
    No observed thrombocytopenia in vivo.

TOLREMO Welcomes Dr. Alan Sandler to Scientific Advisory Board

Retrieved on: 
星期三, 五月 8, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Executive, SAB, Publication, Professor, Abstract, Drug resistance, Vanderbilt University, Internal medicine, Roche, Genentech, Doctor of Philosophy, Rush Medical College, Mirati Therapeutics, Mirati, Indiana University, Senior, CBP, Therapy, Assistant, Drug development, Bristol Myers Squibb, Associate, Division, Pharmaceutical industry

TOLREMO therapeutics AG (TOLREMO) today announced the appointment of Alan Sandler, M.D., to its Scientific Advisory Board (SAB).

Key Points: 
  • TOLREMO therapeutics AG (TOLREMO) today announced the appointment of Alan Sandler, M.D., to its Scientific Advisory Board (SAB).
  • The company’s lead candidate, TT125-802, is a small molecule CBP/p300 bromodomain inhibitor currently advancing through a Phase 1 clinical trial.
  • “Alan brings extensive experience in drug development, including clinical development experience with one of the leading KRAS inhibitors,” said Stefanie Flückiger-Mangual, PhD, Co-founder and Chief Executive Officer of TOLREMO.
  • The team has discovered an exciting pivotal mechanism that governs critical transcriptional resistance pathways,” said Alan Sandler, M.D., Scientific Advisory Board member at TOLREMO.

CBP, Canon Announce Partnership Against Counterfeit Products

Retrieved on: 
星期二, 四月 23, 2024
Safety, Woman, General counsel, Health, Commerce, Intellectual property, Partnership, CBP, IPR, Patent, 3D printing

MELVILLE, N.Y., April 23, 2024 (GLOBE NEWSWIRE) -- Canon U.S.A., Inc. (Canon), a leader in digital imaging solutions and U.S. Customs and Border Protection (CBP) announced today a new partnership to help prevent counterfeit products from entering the United States.

Key Points: 
  • MELVILLE, N.Y., April 23, 2024 (GLOBE NEWSWIRE) -- Canon U.S.A., Inc. (Canon), a leader in digital imaging solutions and U.S. Customs and Border Protection (CBP) announced today a new partnership to help prevent counterfeit products from entering the United States.
  • Under this partnership, which is part of CBP’s Donations Acceptance Program , Canon will donate 328 verification tools to CBP cargo and mail facilities to aid in authenticating a variety of Canon merchandise.
  • CBP’s enforcement efforts are strengthened by stakeholder collaboration and innovative approaches such as the CBP and Canon partnership.
  • This newest donation with Canon will facilitate the identification and removal of counterfeit goods from the U.S. stream of commerce.

Dignari Wins Strategic U.S. Customs and Border Protection Blanket Purchase Agreement

Retrieved on: 
星期一, 四月 15, 2024
Technology, Homeland Security, Air, Security, Transport, Law Enforcement, Emergency Services, Public Policy, Government, Professional Services, Data Analytics, Improper integral, Partnership, CBP, Trust, ESB, BPA, OIT, Management

Today, Dignari, LLC (Dignari) announced its competitive win of the U.S. Customs and Border Protection (CBP) Enterprise Services (ES) Office of Information and Technology (OIT) Blanket Purchase Agreement (BPA) for Enterprise Small Business (ESB) Professional Services.

Key Points: 
  • Today, Dignari, LLC (Dignari) announced its competitive win of the U.S. Customs and Border Protection (CBP) Enterprise Services (ES) Office of Information and Technology (OIT) Blanket Purchase Agreement (BPA) for Enterprise Small Business (ESB) Professional Services.
  • "We are immensely proud of our team's achievement in securing this strategic contract vehicle, further enhancing our commitment to supporting CBP.
  • We extend our gratitude to CBP for the ongoing trust and confidence in our capabilities," remarked Gena Alexa, Founder & CEO of Dignari.
  • This strategic win reinforces Dignari's unwavering commitment to CBP and underscores the strategic value we have brought to the agency for over a decade.

Opna Bio Presents Promising Preclinical Data in Multiple Myeloma with OPN-6602 and in Malignant Mesothelioma with OPN-9840 Showing Significant Tumor Growth Inhibition at the American Association of Cancer Research Annual Meeting

Retrieved on: 
星期三, 四月 10, 2024
Research, Venture Capital, Clinical Trials, Professional Services, Biotechnology, Health, Pharmaceutical, Science, Oncology, CREB-binding protein, NF2, Dexamethasone, FDA, MYC, TGI, Cancer, Bone marrow, Abdomen, Multiple myeloma, Mouse, MYB, Mesothelioma, EP300, Streets of Rage, Doctor of Philosophy, IND, Glomus tumor, TEAD, FMRP, Therapy, BRAF, CBP, Thomas Jefferson University, Patient, Neurofibromatosis, Hippopotamus, Neoplasm, Standard of care, AACR, E1A, IRF4

Data were shared at the American Association of Cancer Research (AACR) Annual Meeting, taking place April 5-10, 2024 in San Diego.

Key Points: 
  • Data were shared at the American Association of Cancer Research (AACR) Annual Meeting, taking place April 5-10, 2024 in San Diego.
  • Multiple myeloma is an aggressive blood cancer derived from malignant plasma cells in the bone marrow.
  • "We are excited to begin our Phase 1 study of OPN-6602 in patients with multiple myeloma this summer.
  • Malignant mesothelioma is a rare and aggressive cancer that primarily affects the lining of the lungs or abdomen.

Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs

Retrieved on: 
星期二, 四月 9, 2024
Well, BRM, Acetyltransferase, Gene expression, Survival, NSCLC, PD, SMARCA2, Neoplasm, Megakaryocyte, Cancer, Prostate, Lung cancer, Protein, IND, EP300, AACR, ATPase, Therapy, BRG1, Safety, CBP, Lilly, Anemia, ID, Thrombocytopenia, Annual general meeting, Pharmaceutical industry

CAMBRIDGE, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced new preclinical data for potential first-in-class medicines including FHD-909, a BRM (SMARCA2) selective inhibitor, selective CBP degrader, and selective EP300 degrader programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting. Foghorn management will hold a conference call and webcast today at 5 p.m. ET to review important pipeline updates.

Key Points: 
  • “Notably, our first-in-class BRM selective inhibitor FHD-909 has demonstrated favorable tolerability and encouraging dose-dependent single agent activity in preclinical models of BRG1 mutated tumors.
  • Additionally, we are applying our long-acting formulation capabilities to our degrader programs, which further enhances the clinical potential of these drug candidates.
  • However, the ATPase domains of BRM and BRG1are 92% identical which has made identifying a selective BRM inhibitor challenging.
  • Attempts to selectively inhibit CBP or EP300 individually have been challenging due to the high homology between the two proteins.

Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting

Retrieved on: 
星期二, 三月 26, 2024
BRM, CBP, Foghorn, Webcast, SMARCA2, EP300, AACR, Conference, Conference call, Acute leukemia, Gene expression, AML, Pharmaceutical industry

CAMBRIDGE, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- March 26, 2024 -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced plans to host a conference call and webcast on April 9th at 5 p.m. ET / 2 p.m. PT. Foghorn management will review key programs in its pipeline, including FHD-286 for acute myelogenous leukemia (AML), and new preclinical data being presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting for potential first-in-class medicines including FHD-909, a BRM (SMARCA2) selective inhibitor, and for the selective CBP and selective EP300 degrader programs.

Key Points: 
  • Company management will review key pipeline programs, including an update on FHD-286 for AML, new preclinical data for the BRM selective inhibitor FHD-909 and for its selective CBP and EP300 degrader programs
    Conference call and webcast on April 9th at 5 p.m.
  • ET / 2 p.m. PT
    CAMBRIDGE, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- March 26, 2024 -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced plans to host a conference call and webcast on April 9th at 5 p.m.
  • ET / 2 p.m. PT.
  • Foghorn management will review key programs in its pipeline, including FHD-286 for acute myelogenous leukemia (AML), and new preclinical data being presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting for potential first-in-class medicines including FHD-909, a BRM (SMARCA2) selective inhibitor, and for the selective CBP and selective EP300 degrader programs.

Mullen Automotive Provides Timeline Update on US Government Ruling for Class 1 EV Cargo Vans

Retrieved on: 
星期三, 三月 13, 2024
CBP, Mullen Technologies, EV, GSA, Government, IBN, RRDS, United States Customs Service

BREA, Calif., March 13, 2024 (GLOBE NEWSWIRE) -- via IBN -- Mullen Automotive, Inc .

Key Points: 
  • BREA, Calif., March 13, 2024 (GLOBE NEWSWIRE) -- via IBN -- Mullen Automotive, Inc .
  • (NASDAQ: MULN ) (“Mullen” or the “Company”), an emerging electric vehicle (“EV”) manufacturer, today announces an update on the U.S. Customs and Border Protection (“CBP”) application for Class 1 EV cargo vans.
  • Based on CBP advice, Mullen and RRDS are now proceeding with the GSA in order to finalize qualification of Mullen to sell Class 1 EV cargo vans to all branches of the U.S. government.
  • “Mullen is well positioned to support the U.S. government’s goal of transitioning its fleet to electric vehicles,” said David Michery, CEO and chairman of Mullen Automotive.

Transmute Executes Phase 5 Contract with US DHS S&T Silicon Valley Innovation Program

Retrieved on: 
星期二, 三月 19, 2024
Data Management, Technology, Transport, Security, Homeland Security, Software, Government Technology, Logistics, Supply Chain Management, Defense, Contracts, Public Policy, Government, United States Customs Service, S&T, DHS, Science, Digital, Silicon, Fraud, CBP, Data management, Red team, VDP, Cryptocurrency

Transmute , a leader in global trade digitalization, proudly announces the launch of their Phase 5 contract with the U.S. Department of Homeland Security (DHS) Science and Technology Directorate’s (S&T) Silicon Valley Innovation Program (SVIP) .

Key Points: 
  • Transmute , a leader in global trade digitalization, proudly announces the launch of their Phase 5 contract with the U.S. Department of Homeland Security (DHS) Science and Technology Directorate’s (S&T) Silicon Valley Innovation Program (SVIP) .
  • This data flow connects the fragmented and still majorly analog solutions that generate billions of paper documents annually.
  • The Phase 5 contract represents a significant advancement for Transmute, unlocking the ability to pursue direct contracts beyond CBP, with any of the 22 DHS agencies.
  • Karyl Fowler, CEO, says, "Transmute is proud to have reached this significant milestone with the U.S. Department of Homeland Security SVIP Team.